Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WINDLAS BIOTECH Gains 11%; BSE HEALTHCARE Index Up 0.7%
Wed, 6 Nov 11:41

WINDLAS BIOTECH Gains 11%; BSE HEALTHCARE Index Up 0.7%Image source: ipopba/www.istockphoto.com

WINDLAS BIOTECH share price has zoomed 11% and is presently trading at Rs 1,147.5.

Meanwhile, the BSE HEALTHCARE index is at 44,249.1 (up 0.7%).

Among the top gainers in the BSE HEALTHCARE index today are Procter & Gamble Health (up 4.0%) and SYNGENE INTERNATIONAL (up 3.0%).

GLAND PHARMA (down 1.6%) and Abbott India (down 1.6%) are among the top losers today.

Over the last one year, WINDLAS BIOTECH has moved up from Rs 368.0 to Rs 1,147.5, registering a gain of Rs 779.5 (up 211.8%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,089.2 to 44,249.1, registering a gain of 57.5% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 209.3%), SUVEN PHARMACEUTICALS (up 134.1%) and Glenmark Pharma (up 131.2%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 80,044.2 (up 0.7%).

The top gainers among the BSE Sensex today are HCl Tech. (up 3.6%) and TCS (up 3.6%). The most traded stocks in the BSE Sensex are ITC and Infosys.

In the meantime, NSE Nifty is at 24,381.8 (up 0.7%). TCS and HCl Tech. are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,958.7 to 80,044.2, registering a gain of 15,085.5 points (up 23.2%).

WINDLAS BIOTECH Financial Update...

WINDLAS BIOTECH net profit grew 11.7% YoY to Rs 135 million for the quarter ended June 2024, compared to a profit of Rs 121 million a year ago. Net sales rose 21.0% to Rs 1,752 million during the period as against Rs 1,448 million in April-June 2023.

For the year ended March 2024, WINDLAS BIOTECH reported 36.5% increase in net profit to Rs 582 million compared to net profit of Rs 426 million during FY23. Revenue of the company grew 23.0% to Rs 6,310 million during FY24.

The current Price to earnings ratio of WINDLAS BIOTECH, based on rolling 12 month earnings, stands at 40.2.


Equitymaster requests your view! Post a comment on "WINDLAS BIOTECH Gains 11%; BSE HEALTHCARE Index Up 0.7%". Click here!